Jon Congleton, CEO, announced the simultaneous release of positive top-line data from the pivotal Launch-HTN and Advance-HTN trials, stating both "successfully achieved statistical significance and ...
Singh maintained guidance that "we'll see top line results released before the end of this calendar quarter, so by the end of this calendar year" for PALISADE-3. Singh projected that top line results ...
Disc Medicine, Inc., a biopharmaceutical company focused on treatments for hematologic diseases, announced positive feedback from its pre-New Drug Application (NDA) meeting with the FDA regarding its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results